We are live on
!
Find out more
VCIM
Velan Capital Investment Management Portfolio holdings
AUM
$160M
1-Year Est. Return
517.12%
This Fund
S&P 500
This Quarter
Est. Return
+104.41%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$220M
AUM Growth
+$48.9M
(+29%)
Cap. Flow
-$3.47M
Cap. Flow
% of AUM
-1.58%
Top 10 Holdings %
Top 10 Hldgs %
90.34%
Holding
27
New
7
Increased
3
Reduced
4
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jasper Therapeutics
JSPR
|
+$6.22M |
| 2 |
TELA Bio
TELA
|
+$4.41M |
| 3 |
Outlook Therapeutics
OTLK
|
+$4.04M |
| 4 |
Aquestive Therapeutics
AQST
|
+$2M |
| 5 |
Milestone Pharmaceuticals
MIST
|
+$1.06M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMGN
Immunogen Inc
IMGN
|
+$5.62M |
| 2 |
Roivant Sciences
ROIV
|
+$5.62M |
| 3 |
Lantheus
LNTH
|
+$4.65M |
| 4 |
ADMA Biologics
ADMA
|
+$3.32M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$2.99M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALIM
1
DELISTED
Alimera Sciences
ALIM
| $53.1M | 24.1% |
13,608,533
| – | – |
|
|
2
Jasper Therapeutics
JSPR
$26.6M
| $42.1M | 19.12% |
1,471,904
+350,000
| +31% | +$6.22M |
|
3
Praxis Precision Medicines
PRAX
$10.2B
| $21.4M | 9.72% |
350,666
+5,000
| +1% | +$224K |
|
4
PUT
iShares Russell 2000 ETF
IWM
$81.5B
| $21M | 9.55% |
100,000
-50,000
| -33% | -$9.97M |
|
5
Heron Therapeutics
HRTX
$63.4M
| $19.4M | 8.79% |
6,986,744
| – | – |
|
6
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $14.2M | 6.46% |
+150,000
| New | +$13.9M |
|
|
7
ADMA Biologics
ADMA
$2.18B
| $10.1M | 4.58% |
1,528,601
-607,499
| -28% | -$3.32M |
|
|
TRML
8
DELISTED
Tourmaline Bio
TRML
| $7.31M | 3.32% |
319,080
| – | – |
|
|
9
Outlook Therapeutics
OTLK
$215M
| $5.97M | 2.71% |
+500,000
| New | +$4.04M |
|
|
OPTN
10
DELISTED
OptiNose
OPTN
| $4.38M | 1.99% |
200,079
-53,045
| -21% | -$1.18M |
|
|
11
TELA Bio
TELA
$41.6M
| $4.23M | 1.92% |
746,087
+668,587
| +863% | +$4.41M |
|
12
Inspire Medical Systems
INSP
$1.73B
| $3.87M | 1.76% |
18,000
| – | – |
|
|
13
Aquestive Therapeutics
AQST
$538M
| $2.56M | 1.16% |
+600,000
| New | +$2M |
|
|
ELEV
14
DELISTED
Elevation Oncology
ELEV
| $2.55M | 1.16% |
497,299
| – | – |
|
15
InspireMD
NSPR
$37.5M
| $2.14M | 0.97% |
904,029
| – | – |
|
16
Geron
GERN
$949M
| $1.65M | 0.75% |
500,000
-278,500
| -36% | -$624K |
|
|
17
Milestone Pharmaceuticals
MIST
$157M
| $1.16M | 0.53% |
+650,000
| New | +$1.06M |
|
18
Rezolute
RZLT
$451M
| $1.02M | 0.46% |
+400,000
| New | +$569K |
|
|
NVNO
19
enVVeno Medical
NVNO
$6.78M
| $937K | 0.43% |
4,921
| – | – |
|
20
Kiora Pharmaceuticals
KPRX
$11.4M
| $777K | 0.35% |
+122,222
| New | +$683K |
|
|
ASLN
21
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| $385K | 0.17% |
+78,125
| New | +$391K |
|
22
Aclaris Therapeutics
ACRS
$867M
| – | – |
-1,761,595
| Closed | -$1.85M |
|
|
APLS
23
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-50,000
| Closed | -$2.99M |
|
24
Immunovant
IMVT
$8.24B
| – | – |
-27,500
| Closed | -$1.16M |
|
|
25
Lantheus
LNTH
$6.59B
| – | – |
-75,000
| Closed | -$4.65M |
|
Similar funds
BFAG
SLG
SMF
LCA
SA
SGCM
RP
PCC
Velan Capital Investment Management's Q1 2024 Portfolio in Review
As of Q1 2024, Velan Capital Investment Management held 27 positions worth $220M, up 29% from $171M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Velan Capital Investment Management's Q1 2024 filing shows 7 new, 3 increased, 4 reduced and 6 closed positions. Its largest new stake was Outlook Therapeutics: 500,000 shares worth $5.97M. The largest sale was Immunogen Inc, an estimated $5.62M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 82% a quarter earlier.
- Velan Capital Investment Management's largest Q1 2024 buy was Outlook Therapeutics: 500,000 shares worth $5.97M.
- Velan Capital Investment Management added most to Jasper Therapeutics in Q1 2024, an estimated $6.22M increase.
- Velan Capital Investment Management's biggest Q1 2024 reduction was ADMA Biologics, cutting an estimated $3.32M.
- Velan Capital Investment Management fully exited Immunogen Inc in Q1 2024, selling an estimated $5.62M.
- Velan Capital Investment Management's ten largest holdings make up 90% of its $220M portfolio in Q1 2024.
- Velan Capital Investment Management opened 7 new positions and closed 6 in Q1 2024.
- Velan Capital Investment Management's portfolio value rose 29% quarter-over-quarter to $220M.
Based on Velan Capital Investment Management's 13F filing for Q1 2024, filed 14 May 2024.